Skip to content

Repaglinide

    Brands

    DEA Class; Rx

    Common Brand Names; Prandin

    • Antidiabetics, Meglitinides Derivatives

    Meglitinide oral hypoglycemic agent; stimulates insulin secretion
    Rapid onset and short duration of action replicates physiological insulin profiles around meals
    Used for the treatment of type 2 diabetes mellitus in adults; not commonly used as monotherapy

    Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

    Hypersensitivity to repaglinide

    Diabetic ketoacidosis

    Type I diabetes mellitus

    Coadministration of gemfibrozil results in increased repaglinide plasma concentration (8-fold increase); may lead to severe hypoglycemia

    • Hypoglycemia (16-31%)
    • Upper respiratory infection (10-16%)
    • Headache (9-11%)
    • Back pain (5-6%)
    • Sinusitis (3-6%)
    • Arthralgia (3-6%)
    • Bronchitis (2-6%)
    • Diarrhea (4-5%)
    • Serious CV events (4%; versus 3% incidence with glyburide and glipizide)
    • Chest pain (2-3%)
    • Constipation (2-3%)
    • Increased LFTs
    • Thrombocytopenia
    • Leukopenia
    • Hemolytic anemia
    • Pancreatitis
    • Visual disturbances
    • Anaphylactoid reactions

    Stress due to infection, fever, trauma, or surgery; may need to discontinue if exposed to stress

    Hepatic/renal insufficiency

    Patients at risk of severe hypoglycemia: Elderly, debilitated, or malnourished; adrenal or pituitary insufficiency

    Myocardial ischemia reported in patients treated concomitantly with NPH-insulin; not indicated for use in combination with NPH-insulin

    Use caution in elderly and malnourished patients

    Pregnancy or lactation

    The use of sulfonylureas may be associated with increased cardiovascular events

    Drugs that inhibit organic anion transporting protein OATP1B1 (eg, cyclosporine) may increase plasma concentrations of repaglinide, which is a substrate for active hepatic uptake transporter OATP1B1

    Limited available data from case reports and case series have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal, or fetal outcomes in women taking repaglinide while pregnant

    Detected in breast milk of rat dams and lowered blood glucose levels were observed in the pups

    Adults

    16 mg/day PO.

    Elderly

    16 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Repaglinide

    tablet

    • 0.5mg
    • 1mg
    • 2mg